Abstract:Linezolid is an oxazolidinone antibiotic exhibiting efficacy against multidrug-resistant (MDR) Gram-positive-related infections. However, its population pharmacokinetic (PopPK) profile in Chinese critically ill children has not been characterized. Optimal dosing regimens should be established according to the PopPK/pharmacodynamic(PD) properties of linezolid in the specific population. This work aims to describe the pharmacokinetic (PK) properties of linezolid, assess the factors affecting interpatient variability, and establish an optimized regimen for children in pediatric intensive care unit (PICU). A single-center, prospective, open-labeled PK study was performed. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was applied to measure the plasma levels during linezolid treatment. PopPK analysis was conducted using Phoenix NLME software. Sixty-three critically ill pediatric patients were included. The data showed good fit for a two-compartment model with linear elimination. Body weight and aspartate aminotransferase (AST) were the most significant covariates explaining variabilities in linezolid PK for the pediatric population. Therapeutic target was defined as the ratio of the area under drug plasma concentration-time curve over 24 h to minimum inhibitory concentration (AUC/MIC) of >80. Different dosing regimens were evaluated using Monte Carlo simulation to determine the optimal dosage strategy for linezolid. Although the probability of target attainment (PTA) was high (>96%) for 10 mg/kg every 8 h at MIC≤1 mg/L, it was lower than 70% at MIC>1 mg/L. Thus, the dosing regimen required adjustment. When the dosing regimen was adjusted to 15 mg/kg every 6 h, the PTA increased from 63.6% to 94.6% at MIC=2 mg/L, thereby indicating higher treatment success. Children with AST of >40 U/L had significant higher AUC than those with AST of ≤40 U/L (205.45 vs. 159.96). Therefore, dosage adjustment was required according to the AST levels. The PopPK characteristics of linezolid in critically ill children were evaluated, and an optimal dosage regimen was constructed based on developmental PopPK/PD model and simulation. (This study has been registered in the Chinese Clinical Trial Registry under no. ChiCTR1900021386.).

Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.

Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients

Clinical Efficacy and Safety of Linezolid in Intensive Care Unit Patients

Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients

Therapy drug monitoring of linezolid in serum of critically ill patients

Developments in the Pharmacokinetic/pharmacodynamic Index of Linezolid: a Step Toward Dose Optimization Using Monte Carlo Simulation in Critically Ill Patients.

Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome

Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Linezolid Pharmacokinetics in Critically Ill Patients: Continuous versus Intermittent Infusion

The clinical features and drug resistance of 10 patients with linezolid-nonsusceptible Enterococcal blood stream infection

Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients

Therapy Drug Monitoring of Linezolid in Serum of Critically Ⅲ Patients

Dosage Regimen and Toxicity Risk Assessment of Linezolid in Sepsis Patients.

Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

Linezolid vs vancomycin for the treatment of Gram-positive cocci infections in intensive care uhit patients:meta-analysis for randomized controlled trials

Prevalence of Potential Drug-Drug Interactions among Intensive Care Unit Patients Receiving Linezolid: a Cross-Sectional Study.

Clinical Significance of Pharmacokinetics Changes of Linezolid in Patients with Different Diseases

Parametric population pharmacokinetics of linezolid: A systematic review

Linezolid: a review of its properties, function, and use in critical care

Linezolid for the treatment of infections caused by Gram-positive pathogens in China